MA53418A1 - Préparation d'absorption transdermique contenant du donépézil stabilisé - Google Patents

Préparation d'absorption transdermique contenant du donépézil stabilisé

Info

Publication number
MA53418A1
MA53418A1 MA53418A MA53418A MA53418A1 MA 53418 A1 MA53418 A1 MA 53418A1 MA 53418 A MA53418 A MA 53418A MA 53418 A MA53418 A MA 53418A MA 53418 A1 MA53418 A1 MA 53418A1
Authority
MA
Morocco
Prior art keywords
donepezil
transdermal absorption
absorption preparation
preparation containing
layer
Prior art date
Application number
MA53418A
Other languages
English (en)
Other versions
MA53418B1 (fr
Inventor
Sun-Woo Jang
Chang-Yell Shin
Hae-Sun Kim
Kwang-Ho Cha
Hyun-Jung Kim
Masaoki Goto
Original Assignee
Dong A St Co Ltd
Km Transderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A St Co Ltd, Km Transderm Ltd filed Critical Dong A St Co Ltd
Publication of MA53418A1 publication Critical patent/MA53418A1/fr
Publication of MA53418B1 publication Critical patent/MA53418B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une préparation d'absorption transdermique pour le traitement de la démence contenant du donépézil et, plus précisément, une préparation d'absorption transdermique pour le traitement de la démence contenant du donépézil, la préparation d'absorption transdermique contenant du donépézil étant constituée d'une couche de support, d'une couche contenant un médicament, et d’une couche de libération, la couche contenant un médicament contenant du donépézil ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif, du monothioglycérol, du thiocyanate (de manière appropriée, du sel de potassium) ou de la diméthylthiourée en tant que stabilisant, et un agent adhésif. La préparation d'absorption transdermique pour traiter la démence selon la présente invention fournit une préparation d'absorption transdermique contenant du donépézil qui peut réduire la production de substances apparentées au donépézil.
MA53418A 2018-12-21 2019-09-05 Préparation d'absorption transdermique contenant du donépézil stabilisé MA53418B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180167289A KR102115102B1 (ko) 2018-12-21 2018-12-21 안정화된 도네페질 함유 경피 흡수제제
PCT/KR2019/011483 WO2020130287A1 (fr) 2018-12-21 2019-09-05 Préparation d'absorption transdermique contenant du donépézil stabilisé

Publications (2)

Publication Number Publication Date
MA53418A1 true MA53418A1 (fr) 2022-08-31
MA53418B1 MA53418B1 (fr) 2023-03-31

Family

ID=70914737

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53418A MA53418B1 (fr) 2018-12-21 2019-09-05 Préparation d'absorption transdermique contenant du donépézil stabilisé

Country Status (16)

Country Link
US (1) US12168073B2 (fr)
EP (1) EP3900711B1 (fr)
JP (1) JP7193643B2 (fr)
KR (1) KR102115102B1 (fr)
CN (1) CN113260356B (fr)
AU (1) AU2019405846B2 (fr)
CA (1) CA3124070C (fr)
CL (1) CL2021001463A1 (fr)
ES (1) ES2972123T3 (fr)
MA (1) MA53418B1 (fr)
MX (1) MX2021007078A (fr)
PE (1) PE20211791A1 (fr)
PH (1) PH12021551453A1 (fr)
PL (1) PL3900711T3 (fr)
WO (1) WO2020130287A1 (fr)
ZA (1) ZA202104943B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102218593B1 (ko) * 2020-05-13 2021-02-22 동아에스티 주식회사 안정성이 향상된 도네페질 함유 경피 흡수제제
JP2022122784A (ja) * 2021-02-10 2022-08-23 コスメディ製薬株式会社 酸化防止剤含有経皮吸収製剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS609727B2 (ja) * 1980-09-27 1985-03-12 日東電工株式会社 貼り付け用膏体
US5146730A (en) 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US6372760B1 (en) 1999-03-31 2002-04-16 Eisai Co., Ltd. Stabilized composition comprising antidementia medicament
KR20050037405A (ko) 2001-10-17 2005-04-21 히사미쯔 제약 주식회사 경피 흡수형 제제
CA2592605C (fr) 2004-12-27 2010-12-07 Eisai R&D Management Co., Ltd. Methode de stabilisation d'un medicament contre la demence
US20080138388A1 (en) 2005-02-04 2008-06-12 Hisamitsu Pharmaceutical Co., Inc. Transdermal Absorption Patch
EP2098234A4 (fr) 2006-12-01 2012-03-21 Nitto Denko Corp Préparation adhésive pour la peau comprenant du donépézil stabilisé
JP5237112B2 (ja) * 2006-12-01 2013-07-17 日東電工株式会社 経皮吸収製剤
KR101408488B1 (ko) 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법
EP2638906A1 (fr) * 2006-12-01 2013-09-18 Nitto Denko Corporation Préparation d'adhésif cutané comprenant du donépézil stabilisé
KR101454362B1 (ko) 2008-03-24 2014-10-23 아이큐어 주식회사 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제
US20090291127A1 (en) 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
AU2010309030B2 (en) 2009-10-21 2013-10-31 Teikoku Seiyaku Co., Ltd. Transdermally absorbable donepezil-containing preparation
CN102614109B (zh) * 2012-04-16 2013-11-13 上海现代药物制剂工程研究中心有限公司 基于多层液晶骨架的、含有活性物质的凝胶组合物及制法
KR101770675B1 (ko) 2013-01-30 2017-08-23 에스케이케미칼주식회사 도네페질-함유 경피흡수제제 및 그의 제조방법
KR101485822B1 (ko) 2014-01-22 2015-01-23 주식회사 대웅제약 도네페질 또는 그의 염을 함유하는 경피흡수제제
KR20160120778A (ko) 2014-02-20 2016-10-18 날 파마슈티칼 그룹 리미티드 도네페질을 함유하는 경피흡수제제
CN106714787A (zh) * 2014-09-25 2017-05-24 富士胶片株式会社 含丙泊酚的水包油型乳液组合物及其制造方法
PT3235494T (pt) 2014-12-18 2020-03-05 Icure Pharm Inc Preparação transdérmica contendo donepezilo como ingrediente ativo
WO2017073516A1 (fr) * 2015-10-26 2017-05-04 久光製薬株式会社 Timbre cutané adhésif
US20180008612A1 (en) 2016-07-11 2018-01-11 Taho Pharmaceuticals Ltd. Transdermal delivery system containing galantamine or salts thereof
JP7071330B2 (ja) 2016-07-27 2022-05-18 コリウム， インコーポレイテッド 炭酸水素ナトリウムのｉｎ ｓｉｔｕ変換で促進されたアミン薬物の経皮送達
KR102024996B1 (ko) 2017-12-27 2019-09-25 동아에스티 주식회사 도네페질을 함유하는 치매 치료용 경피흡수제제
US12582637B2 (en) 2018-08-31 2026-03-24 Arctic Therapeutics Hf Topical formulation for intradermal application and uses thereof

Also Published As

Publication number Publication date
CN113260356B (zh) 2024-09-17
EP3900711A4 (fr) 2022-11-30
JP7193643B2 (ja) 2022-12-20
ES2972123T3 (es) 2024-06-11
BR112021012142A2 (pt) 2021-09-08
KR102115102B1 (ko) 2020-05-26
CA3124070C (fr) 2024-03-12
MA53418B1 (fr) 2023-03-31
MX2021007078A (es) 2021-09-10
JP2022514037A (ja) 2022-02-09
US20220047524A1 (en) 2022-02-17
AU2019405846B2 (en) 2022-10-20
ZA202104943B (en) 2022-08-31
PL3900711T3 (pl) 2024-07-22
EP3900711A1 (fr) 2021-10-27
CL2021001463A1 (es) 2021-12-10
EP3900711B1 (fr) 2024-03-06
WO2020130287A1 (fr) 2020-06-25
PH12021551453A1 (en) 2022-04-18
CN113260356A (zh) 2021-08-13
AU2019405846A1 (en) 2021-06-17
US12168073B2 (en) 2024-12-17
PE20211791A1 (es) 2021-09-09
EP3900711C0 (fr) 2024-03-06
CA3124070A1 (fr) 2020-06-25

Similar Documents

Publication Publication Date Title
Lee et al. Endothelial progenitor cells in cardiovascular diseases
SA522433129B1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
Valenti et al. Biphasic effect of nitric oxide on testosterone and cyclic GMP production by purified rat Leydig cells cultured in vitro
Sun et al. NAD depletion mediates cytotoxicity in human neurons with autophagy deficiency
CL2010001467A1 (es) Compuestos derivados de fenil-imidazol sustituido con un heteroaromatico biciclico; composicion farmaceutica que los comprende; y su uso como inhibidores de la pde10a para tratar trastornos neurodegenerativos o psiquiatricos como alzheimer, demencia alcoholica, trastorno del aprendizaje, esquizofrenia, adiccion a las drogas.
MA38698A1 (fr) Système d'administration transdermique
MA39040A1 (fr) Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA42811B1 (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
EP3699174A4 (fr) Composition pour la prévention ou le traitement de maladies liées au tnf, contenant un nouveau dérivé en tant que principe actif, et procédé d'inhibition de l'activité du tnf à l'aide de celle-ci
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
MA33593B1 (fr) Composés hétérocycliques et leurs utilisations
MA56661B1 (fr) Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide
MA40769B1 (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
EP3838898C0 (fr) Dérivé d'isoindolin-1-one, procédé de préparation de celui-ci, et composition pharmaceutique le contenant en tant que composant actif pour la prévention ou le traitement du cancer
Liu et al. Phosphodiesterase inhibitor modulation of brain microvascular endothelial cell barrier properties
MA38358B1 (fr) Formulations de composés organiques
MA53418B1 (fr) Préparation d'absorption transdermique contenant du donépézil stabilisé
WO2014188329A3 (fr) Système thérapeutique transdermique pour dosage à libération prolongée de pramipexole dans le traitement de troubles neurologiques
EP3882242A4 (fr) Composé inhibant la liaison yap-tead et composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé en tant que principe actif
EP3539951A4 (fr) Nouveau composé de pyrimidine, son procédé de préparation et composition pharmaceutique le contenant en tant que principe actif pour la prévention ou le traitement du cancer et des maladies inflammatoires
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
EP3760626A4 (fr) Nouveau composé et composition pour la prévention, l'amélioration ou le traitement de la fibrose ou de la stéatohépatite non alcoolique le comprenant en tant que principe actif
MA46268B1 (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma